Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):276–282. doi: 10.1038/bjc.1989.57

Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.

R A Cowan 1, M Jones 1, M Harris 1, W P Steward 1, J A Radford 1, J Wagstaff 1, D P Deakin 1, D Crowther 1
PMCID: PMC2247014  PMID: 2930692

Abstract

An analysis of prognostic factors has been performed on 260 patients with high and intermediate grade non-Hodgkin's lymphoma (NHL) treated over an 11-year period between 1975 and 1986. The overall 5-year survival rate was 50% with a median follow-up of 72 months. Over 20 clinical, radiological and laboratory parameters have been studied, including variables reported to be important indicators of prognosis in previous series, and these variables have been subjected to univariate and multivariate analysis. Attainment of complete remission (CR) was the most important predictor of overall survival, low serum lactate dehydrogenase (LDH), limited stage disease and a high serum albumin were also independently associated with prolonged survival in multivariate analysis. After removing remission status from the model, Ann Arbor clinical stage became the most significant pre-treatment prognostic indicator. Sixty-five per cent of patients achieved CR, and a discriminant analysis showed that failure to attain CR was associated with advanced stage disease, constitutional symptoms, increasing patient age, a low serum albumin and the presence of bulk disease. Advanced clinical stage and an elevated serum LDH predicted independently for a poor relapse-free survival, and reduced overall survival following CR. There was no significant correlation between histological subtype in the Kiel classification and prognosis. This study confirms the prognostic significance of remission status and Ann Arbor clinical stage, and illustrates additional factors including serum levels of albumin and LDH, which serve to enhance the pre-treatment prognostic evaluation of patients with unfavourable histology NHL.

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armitage J. O., Dick F. R., Corder M. P., Garneau S. C., Platz C. E., Slymen D. J. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer. 1982 Nov 1;50(9):1695–1702. doi: 10.1002/1097-0142(19821101)50:9<1695::aid-cncr2820500907>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  2. BIERMAN H. R., HILL B. R., REINHARDT L., EMORY E. Correlation of serum lactic dehydrogenase activity with the clinical status of patients with cancer, lymphomas, and the leukemias. Cancer Res. 1957 Aug;17(7):660–667. [PubMed] [Google Scholar]
  3. Bauer K. D., Merkel D. E., Winter J. N., Marder R. J., Hauck W. W., Wallemark C. B., Williams T. J., Variakojis D. Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res. 1986 Jun;46(6):3173–3178. [PubMed] [Google Scholar]
  4. Blackledge G., Bush H., Chang J., Crowther D., Deakin D. P., Dodge O. G., Garrett J. V., Palmer M., Pearson D., Scarffe J. H. Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group). Eur J Cancer. 1980 Nov;16(11):1459–1468. doi: 10.1016/0014-2964(80)90056-0. [DOI] [PubMed] [Google Scholar]
  5. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  6. Christensson B., Tribukait B., Linder I. L., Ullman B., Biberfeld P. Cell proliferation and DNA content in non-Hodgkin's lymphoma. Flow cytometry in relation to lymphoma classification. Cancer. 1986 Sep 15;58(6):1295–1304. doi: 10.1002/1097-0142(19860915)58:6<1295::aid-cncr2820580620>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  7. Ferraris A. M., Giuntini P., Gaetani G. F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979 Oct;54(4):928–932. [PubMed] [Google Scholar]
  8. Fisher R. I., DeVita V. T., Jr, Hubbard S. M., Longo D. L., Wesley R., Chabner B. A., Young R. C. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar;98(3):304–309. doi: 10.7326/0003-4819-98-3-304. [DOI] [PubMed] [Google Scholar]
  9. Fisher R. I., Hubbard S. M., DeVita V. T., Berard C. W., Wesley R., Cossman J., Young R. C. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood. 1981 Jul;58(1):45–51. [PubMed] [Google Scholar]
  10. Gams R. A., Rainey M., Dandy M., Bartolucci A. A., Silberman H., Omura G. Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. J Clin Oncol. 1985 Sep;3(9):1188–1195. doi: 10.1200/JCO.1985.3.9.1188. [DOI] [PubMed] [Google Scholar]
  11. Hagberg H., Siegbahn A. Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma. Scand J Haematol. 1983 Jul;31(1):49–56. doi: 10.1111/j.1600-0609.1983.tb02136.x. [DOI] [PubMed] [Google Scholar]
  12. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  13. Isaacson P. G., O'Connor N. T., Spencer J., Bevan D. H., Connolly C. E., Kirkham N., Pollock D. J., Wainscoat J. S., Stein H., Mason D. Y. Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet. 1985 Sep 28;2(8457):688–691. doi: 10.1016/s0140-6736(85)92930-7. [DOI] [PubMed] [Google Scholar]
  14. Jagannath S., Velasquez W. S., Tucker S. L., Fuller L. M., McLaughlin P. W., Manning J. T., North L. B., Cabanillas F. C. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol. 1986 Jun;4(6):859–865. doi: 10.1200/JCO.1986.4.6.859. [DOI] [PubMed] [Google Scholar]
  15. Jagannath S., Velasquez W. S., Tucker S. L., Manning J. T., McLaughlin P., Fuller L. M. Stage IV diffuse large-cell lymphoma: a long-term analysis. J Clin Oncol. 1985 Jan;3(1):39–47. doi: 10.1200/JCO.1985.3.1.39. [DOI] [PubMed] [Google Scholar]
  16. Juneja S. K., Cooper I. A., Hodgson G. S., Wolf M. M., Ding J. C., Ironside P. N., Thomas R. J., Parkin J. D. DNA ploidy patterns and cytokinetics of non-Hodgkin's lymphoma. J Clin Pathol. 1986 Sep;39(9):987–992. doi: 10.1136/jcp.39.9.987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kaminski M. S., Coleman C. N., Colby T. V., Cox R. S., Rosenberg S. A. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med. 1986 Jun;104(6):747–756. doi: 10.7326/0003-4819-104-6-747. [DOI] [PubMed] [Google Scholar]
  18. Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985 May;102(5):596–602. doi: 10.7326/0003-4819-102-5-596. [DOI] [PubMed] [Google Scholar]
  19. Koziner B., Little C., Passe S., Thaler H. T., Sklaroff R., Straus D. J., Lee B. J., Clarkson B. D. Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables. Cancer. 1982 Apr 15;49(8):1571–1579. doi: 10.1002/1097-0142(19820415)49:8<1571::aid-cncr2820490809>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  20. Laurence J., Coleman M., Allen S. L., Silver R. T., Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med. 1982 Aug;97(2):190–195. doi: 10.7326/0003-4819-97-2-190. [DOI] [PubMed] [Google Scholar]
  21. Mackintosh J. F., Cowan R. A., Jones M., Harris M., Deakin D. P., Crowther D. Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1988 Oct;24(10):1617–1622. doi: 10.1016/0277-5379(88)90054-5. [DOI] [PubMed] [Google Scholar]
  22. Morgan D. R., Williamson J. M., Quirke P., Clayden A. D., Smith M. E., O'Brien C. J., Allison D. L., Child J. A., Bird C. C. DNA content and prognosis of non-Hodgkin's lymphoma. Br J Cancer. 1986 Oct;54(4):643–649. doi: 10.1038/bjc.1986.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nabholtz J. M., Friedman S., Collin F., Guerrin J. Modification of Kiel and working formulation classifications for improved survival prediction in non-Hodgkin's lymphoma. J Clin Oncol. 1987 Oct;5(10):1634–1639. doi: 10.1200/JCO.1987.5.10.1634. [DOI] [PubMed] [Google Scholar]
  24. Nathwani B. N., Dixon D. O., Jones S. E., Hartsock R. J., Rebuck J. W., Byrne G. E., Jr, Sheehan W. W., Kim H., Coltman C. A., Jr, Rappaport H. The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group. Blood. 1982 Nov;60(5):1068–1074. [PubMed] [Google Scholar]
  25. Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pinkus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Canellos G. P. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986 Jun;104(6):757–765. doi: 10.7326/0003-4819-104-6-757. [DOI] [PubMed] [Google Scholar]
  26. Steward W. P., Todd I. D., Harris M., Jones J. M., Blackledge G., Wagstaff J., Anderson H., Wilkinson P. M., Crowther D. A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1984 Jul;20(7):881–889. doi: 10.1016/0277-5379(84)90159-7. [DOI] [PubMed] [Google Scholar]
  27. Sweet D. L., Golomb H. M., Ultmann J. E., Miller J. B., Stein R. S., Lester E. P., Mintz U., Bitran J. D., Streuli R. A., Daly K. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med. 1980 Jun;92(6):785–790. doi: 10.7326/0003-4819-92-6-785. [DOI] [PubMed] [Google Scholar]
  28. Todd M. B., Portlock C. S., Farber L. R., Holford T. R., Bertino J. R. Prognostic indicators in diffuse large-cell (histiocytic) lymphoma. Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):593–601. doi: 10.1016/0360-3016(86)90068-4. [DOI] [PubMed] [Google Scholar]
  29. Vokes E. E., Ultmann J. E., Golomb H. M., Gaynor E. R., Ferguson D. J., Griem M. L., Oleske D. Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol. 1985 Oct;3(10):1309–1317. doi: 10.1200/JCO.1985.3.10.1309. [DOI] [PubMed] [Google Scholar]
  30. Wagstaff J., Todd I., Deakin D., Wilkinson P., Scarffe J. H., Harris M., Jones M., Crowther D. A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 1987;20(1):53–58. doi: 10.1007/BF00252960. [DOI] [PubMed] [Google Scholar]
  31. Young G. A., Hedley D. W., Rugg C. A., Iland H. J. The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival material. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1497–1504. doi: 10.1016/0277-5379(87)90092-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES